ENTX · Entera Bio Ltd. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | - | $0 | $0 | $0 | - | $42.0K | $57.0K | - | - |
| Cost of Revenue | $0 | - | $0 | $0 | $0 | - | $42.0K | $48.0K | - | - |
| Gross Profit | $0 | - | $0 | $0 | $0 | - | $0 | $9.0K | - | - |
| R&D | $2.25M | - | $1.64M | $1.52M | $1.12M | - | $1.48M | $1.09M | $735.0K | - |
| SG&A | $128.0K | - | $122.0K | $134.0K | $1.44M | - | $1.54M | $1.09M | $1.33M | - |
| Total Operating Expenses | $3.54M | - | $3.26M | $2.67M | $2.56M | - | $3.02M | $2.17M | $2.06M | - |
| D&A | $7.0K | - | - | - | $8.0K | - | - | - | $13.0K | - |
| Operating Income | ($3.54M) | - | ($3.26M) | ($2.67M) | ($2.56M) | - | ($3.02M) | ($2.17M) | ($2.06M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | $0 | - | - | - |
| Net Income | ($3.50M) | - | ($3.20M) | ($2.66M) | ($2.57M) | - | ($3.02M) | ($2.15M) | ($2.02M) | - |
| EPS - Basic | $0.07 | - | $0.07 | $0.06 | $0.06 | - | $0.08 | $0.06 | $0.05 | - |
| EPS - Diluted | $0.07 | - | $0.07 | $0.06 | $0.06 | - | $0.08 | $0.06 | $0.05 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.14M | $7.11M | $8.57M | $10.86M | $12.57M | $8.66M | $6.92M | $9.06M | $9.19M | $11.02M |
| Accounts Receivable | - | $0 | $0 | $0 | $126.0K | $126.0K | $42.0K | $57.0K | - | $0 |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $274.0K | $448.0K | $216.0K | $383.0K | $134.0K | $132.0K | $184.0K | $69.0K | $66.0K | $83.0K |
| Current Assets | $12.49M | $15.30M | $17.01M | $19.31M | $21.22M | $8.97M | $7.34M | $9.60M | $9.75M | $11.26M |
| Total Assets | $13.13M | $15.99M | $17.41M | $19.67M | $21.60M | $9.39M | $7.74M | $10.04M | $10.24M | $11.77M |
| Current Liabilities | $1.58M | $2.20M | $1.57M | $1.84M | $1.62M | $1.18M | $1.11M | $1.29M | $1.12M | $1.09M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $2.44M | $2.89M | $2.17M | $2.41M | $2.22M | $1.31M | $1.29M | $1.50M | $1.38M | $1.38M |
| Stockholders' Equity | $10.69M | $13.10M | $15.23M | $17.26M | $19.38M | $8.08M | $6.45M | $8.53M | $8.86M | $10.39M |
| Retained Earnings | ($128.87M) | ($125.37M) | ($122.35M) | ($119.15M) | ($116.49M) | ($113.93M) | ($111.57M) | ($108.55M) | ($106.40M) | ($104.39M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($3.09M) | - | - | - | ($1.40M) | - | - | - | ($1.86M) | - |
| Investing Cash Flow | $0 | - | - | - | ($8.0K) | - | - | - | $0 | - |
| Financing Cash Flow | $130.0K | - | - | - | $13.34M | - | - | - | $30.0K | - |
| CapEx | $0 | - | - | - | $8.0K | - | - | - | $0 | - |
| Free Cash Flow | ($3.09M) | - | - | - | ($1.41M) | - | - | - | ($1.86M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | 0.0% | 15.8% | - | - |
| Operating margin | - | - | - | - | - | - | -7192.9% | -3798.2% | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | -7192.9% | -3763.2% | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.88 | - | - | - | 0.55 | - | - | - | 0.92 | - |
| R&D / Revenue | - | - | - | - | - | - | 3516.7% | 1905.3% | - | - |
| SG&A / Revenue | - | - | - | - | - | - | 3676.2% | 1908.8% | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -26.7% | - | -18.4% | -13.5% | -11.9% | - | -39.0% | -21.4% | -19.7% | - |
| Return on equity | -32.8% | - | -21.0% | -15.4% | -13.2% | - | -46.8% | -25.1% | -22.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 7.93 | 6.94 | 10.83 | 10.47 | 13.07 | 7.63 | 6.61 | 7.41 | 8.70 | 10.32 |
| Quick ratio | 7.93 | 6.94 | 10.83 | 10.47 | 13.07 | 7.63 | 6.61 | 7.41 | 8.70 | 10.32 |
| Cash ratio | 2.63 | 3.23 | 5.46 | 5.89 | 7.75 | 7.36 | 6.22 | 7.00 | 8.20 | 10.10 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.23 | 1.22 | 1.14 | 1.14 | 1.11 | 1.16 | 1.20 | 1.18 | 1.16 | 1.13 |
| Liabilities / Assets | 0.19 | 0.18 | 0.12 | 0.12 | 0.10 | 0.14 | 0.17 | 0.15 | 0.13 | 0.12 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.00 | 0.00 | 0.00 | - | 0.01 | 0.01 | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | 365d | 365d | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | 1599d | 525d | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 15.9x | - | 27.4x | 31.7x | 28.3x | - | 23.8x | 30.7x | 33.4x | - |
| P / B | 5.0x | - | 5.9x | 5.2x | 3.8x | - | 11.1x | 8.0x | 6.9x | - |
| P / S | - | - | - | - | - | - | 1703.0x | 1197.3x | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | -100.0% | -100.0% | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | -19.4% | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -38.1% | - | -7.8% | -23.2% | -24.3% | - | -26.6% | 7.1% | 6.8% | - |
| Net income growth (YoY) | -36.5% | - | -5.9% | -23.8% | -27.3% | - | -27.0% | 7.7% | 7.9% | - |
| EPS growth (YoY) | 16.7% | - | -12.5% | 0.0% | 20.0% | - | 0.0% | -25.0% | -37.5% | - |
| EPS CAGR (3y) | -4.4% | - | -14.0% | -15.7% | - | - | - | -34.1% | - | - |
| EPS CAGR (5y) | - | - | - | -12.9% | - | - | - | - | - | - |
| FCF growth (YoY) | -118.8% | - | - | - | 24.2% | - | - | - | -14.9% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -44.9% | 62.1% | 136.1% | 102.3% | 118.7% | -22.2% | 3.5% | 3.6% | -12.1% | -11.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$502.0K totalService$502.0K · 100.0%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Entera Bio Ltd. against the 5 most active filers in the same SIC group.